New job for former CAT CTO
Naarden – Dutch antibody specialist Pan-Genetics BV has closed a €13 million series B round led by ABN AMRO Capital, with participation from Credit Agricole Private Equity and Series A seed investor Index Ventures. In connection with the investment, the company appointed Kevin Johnson, former board member and CTO at Cambridge Antibody Technology, as Chief Executive Officer. The funds will enable PanGenetics to continue clinical development of its human CD40 antagonist, PG102, with a view to filing an IND Q1 2007. An earlier version of this antibody has already been in an open label clinical trial, where it showed safety and signs of efficacy. The company will conclude in-licensing of additional drug candidates.